End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.55 CNY | -1.29% | +1.21% | -34.19% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 27.79 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.19% | 765M | - | ||
+12.13% | 40.03B | B | ||
+0.16% | 18.83B | B- | ||
-14.13% | 2.41B | D+ | ||
+4.89% | 1.76B | C+ | ||
+24.59% | 1.19B | - | ||
-35.08% | 745M | B- | ||
-6.50% | 676M | - | ||
+22.63% | 490M | - | - | |
+26.77% | 489M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301101 Stock
- Ratings Mingyue Optical Lens Co.,Ltd.